Canadian Sec - Free Realtime Quote CAD

BioNxt Solutions Inc. (BNXT.CN)

0.4500

+0.0150

+(3.45%)

As of 10:53:49 AM EDT. Market Open.

BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization

VANCOUVER, BC / ACCESS Newswire / May 5, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its first national ...

ACCESS Newswire 9 hours ago

BNXTF
BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements

VANCOUVER, BC / ACCESS Newswire / May 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), announces that its annual financial statements for the year ended December 31, 2024, the related management discussion ...

ACCESS Newswire 3 days ago

BNXTF
BioNxt Solutions Prepares for Human Bioequivalence Study For MS

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation ...

ACCESS Newswire 12 days ago

BNXTF
BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / March 14, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce ...

ACCESS Newswire last month

BNXTF
BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / February 28, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT), is pleased ...

ACCESS Newswire 2 months ago

BNXTF
BioNxt Solutions Announces Debenture Unit Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT), announces ...

ACCESS Newswire 2 months ago

BNXTF
Clarification of Promotional Activities

VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT) reports a clarification to its news release dated January 31, 2025, at the request of the Canadian Investment ...

ACCESS Newswire 2 months ago

BNXTF
BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion

VANCOUVER, BC / ACCESS Newswire / February 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report on several major ...

ACCESS Newswire 2 months ago

BNXTF
BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is excited to announce a major milestone in its research and development journey. The company ...

ACCESS Newswire 3 months ago

BNXTF
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the expansion of its intellectual property portfolio with the filing ...

ACCESS Newswire 4 months ago

BNXTF
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment

VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development ...

ACCESS Newswire 4 months ago

BNXTF
BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, ...

ACCESS Newswire 4 months ago

BNXTF
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce the expansion of its next-generation product pipeline. This includes proprietary Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral ...

ACCESS Newswire 5 months ago

BNXTF
BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that it has initiated the nationalization process for the filing of a family of patents for ...

ACCESS Newswire 6 months ago

BNXTF
Terry Lynch Joins BioNxt as Capital Markets Advisor

VANCOUVER, BC / ACCESSWIRE / October 7, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch has joined the BioNxt team as a capital markets advisor. Mr. Lynch brings ...

ACCESS Newswire 6 months ago

BNXTF
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities

VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to provide an update on its flagship sublingual Cladribine drug formulation program for the treatment ...

ACCESS Newswire 7 months ago

BNXTF
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

VANCOUVER, BC / ACCESSWIRE / September 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to report that the European Patent Office ("EPO") has issued a positive international examination report ...

ACCESS Newswire 7 months ago

BNXTF
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract ...

ACCESS Newswire 8 months ago

BNXTF
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development

VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a statement of work ("SOW") with a German-based international contract research, ...

ACCESS Newswire 9 months ago

BNXTF
BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization

VANCOUVER, BC / ACCESSWIRE / July 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a master services agreement ("MSA") with a German-based international contract research, ...

ACCESS Newswire 9 months ago

BNXTF

Performance Overview

Return	BNXT.CN	S&P/TSX Composite index (^GSPTSE)
YTD	+21.62%	+1.70%
1-Year	+25.00%	+14.09%
3-Year	-51.09%	+20.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioNxt Solutions Inc. (BNXT.CN)

BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization

BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements

BioNxt Solutions Prepares for Human Bioequivalence Study For MS

BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement

BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement

BioNxt Solutions Announces Debenture Unit Financing

Clarification of Promotional Activities

BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion

BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities

BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment

BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide

BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

Terry Lynch Joins BioNxt as Capital Markets Advisor

BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities

BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development

BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization

Performance Overview